Xantomit^®

Mitoxantrone

Product Information

Proprietary Name: Xantomit®
Generic Name: Mitoxantrone
Dosage Form: Vial
Strengths: 20 mg/10 ml
Indications: Multiple Sclerosis, Prostate Cancer, Hepatocellular Carcinoma, Breast Cancer, Non-Hodgkin’s Lymphoma, Acute Non-Lymphocytic Leukemia (ANLL)

Download Leaflet

Oncology

Xantomit®

Mitoxantrone is indicated for the treatment of multiple sclerosis, prostate cancer, hepatocellular carcinoma, breast cancer, non-hodgkin’s lymphoma, and acute non-lymphocytic leukemia (ANLL).